Flash e-reader

 Go to e-reader chapter








Table 7.6i

Immunosuppression Use for Antirejection Treatment from Transplant

to One Year Following Transplantation, 1999 to 2008

Recipients with Pancreas After Kidney (PAK) Transplants

  Year of Transplant
1999 2000 2001 2002 2003 2004 2005 2006 2007 2008
Transplants 220 305 305 375 344 420 343 293 261 213
Tx with Antirejection Treatments 57 65 45 43 61 59 46 32 33 16
Antibodies Any in Category 75.4% 53.8% 60.0% 48.8% 65.6% 59.3% 76.1% 68.8% 72.7% 43.8%
Atgam/NRATG/NRATS 1.8% 1.5% 2.2% 0.0% 3.3% 0.0% 0.0% 0.0% 0.0% 0.0%
OKT3 63.2% 35.4% 26.7% 25.6% 13.1% 15.3% 13.0% 15.6% 12.1% 12.5%
Thymoglobulin 22.8% 21.5% 33.3% 30.2% 45.9% 44.1% 63.0% 59.4% 63.6% 31.3%
Zenapax 1.8% 1.5% 2.2% 2.3% 6.6% 0.0% 4.3% 3.1% 3.0% 12.5%
Simulect 0.0% 4.6% 4.4% 0.0% 4.9% 0.0% 2.2% 3.1% 0.0% 0.0%
Campath 0.0% 0.0% 0.0% 0.0% 27.9% 8.5% 6.5% 3.1% 6.1% 0.0%
Corticosteroids Any in Category 84.2% 87.7% 86.7% 90.7% 68.9% 79.7% 63.0% 68.8% 84.8% 87.5%
Steroids 84.2% 87.7% 86.7% 90.7% 68.9% 79.7% 63.0% 68.8% 84.8% 87.5%
Antimetabolites Any in Category 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Methotrexate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%


Source: OPTN/SRTR Data as of October 1, 2010.

Individual drug percentages will not necessarily add up to the drug category percentages, as patients may

be prescribed more than one drug within the same category.